Press Releases - Sami Labs

Disclaimer

US-FDA: This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

Usage disclaimer: The information pertaining to any marketing materials by Sabinsa, is for general purposes only. Users are urged to check the validity of patents if any, on any Sabinsa items for their intended use.

EFSA: This statement has not been evaluated by the EFSA. This product is not intended to diagnose, treat, cure, or prevent any disease.

Australia: Please note as an ingredient supplier the information contained in this website is for marketers of finished products formulations and is not intended as consumer advice. Marketers should ensure finished products are lawful and comply with the regulations of the countries in which these items are sold. Every care has been taken to ensure the accuracy of the information provided at the time of publication.

Sabinsa Named a Top New Jersey Company for Its Dynamic Growth

Sabinsa Issued New U.S. Patent for LactoSpore® Based upon Published Research Confirming Ability to Reverse Depression Symptoms in Patients Suffering from IBS

Sabinsa’s Pterostilbene in Silbinol® Subject of Published Study

Sabinsa’s Parent Dubbed Most Trusted Nutraceutical Company

Government of Karnataka State, India Recognizes the Sami- Sabinsa Group with Three Awards for Export Excellence

Research Finds Sabinsa’s Curcumin C3 Complex® in Combination with BioPerine® Effective for Non-Alcoholic Fatty Liver Disease

ABOUT SAMI LABS

HEADQUARTERS

CERTIFICATES

CONTACT US